ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1556

Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome

Sinem Nihal Esatoglu1, Sabriye Guner1, Sevim Guler2, Gulen Hatemi1, Nuray Kepil3, Yusuf Ziya Erzin4, Aykut Ferhat Celik4 and Ibrahim Hatemi4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey

Meeting: ACR Convergence 2023

Keywords: Behçet's Syndrome, Disease-Modifying Antirheumatic Drugs (Dmards), surgery, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gastrointestinal involvement of Behçet’s syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics, treatments, and long-term prognosis of GIBS patients who underwent abdominal surgical interventions.

Methods: We conducted a retrospective chart review of all Behçet syndrome (BS) patients recorded between 1978 and 2022 to identify those with GIBS who had undergone abdominal surgery for GIBS. Data were collected regarding demographics, type of interventions, treatment, recurrences, and outcomes. Relapse was defined as the presence of endoscopic or clinical activity with a positive fecal calprotectin test following bowel resection.

Results: Among our 11,200 BS patients, 119 (1%) had GIBS, and 27 (24%) of these GIBS patients (19 male, mean age: 49 ± 11 years) had undergone abdominal surgery (Table). BS was already diagnosed at the time of gastrointestinal involvement in 19 (65%) patients while 10 were diagnosed with BS with the development of gastrointestinal involvement. All except 1 patient who underwent ileocecal resection due to refractory disease, were diagnosed with GIBS following abdominal surgery. Perforation (n=18, 62%) and massive hematochezia (n=6, 21%) were the main reasons for surgery. The type of surgery was bowel resection in 25 patients, primary closure in 2 and diagnostic laparotomy in 2 patients. Two patients with refractory GIBS had died due to extensive vascular involvement (n=1) and secondary amyloidosis (n=1). Among the 25 patients who underwent bowel resection, 14 (56%) experienced a relapse during a median follow-up of 24 (IQR: 1.75-36) months. Of these 14 patients, 12 had only one relapse. At the time of relapse, 4 (29%) patients required a reoperation. The remaining 11 patients did not experience any relapses during a median follow-up of 13 (IQR: 10-22) months. Postoperative azathioprine treatment was initiated in 11 patients, with 3 of them also receiving a TNF inhibitor. Three of these 11 patients experienced a relapse while among the 14 patients who did not receive postoperative immunosuppressive treatment, 11 had a relapse (27% vs 79%; p=0.01). The use of postoperative immunosuppressive treatment was associated with a reduced risk of relapse (OR: 0.10; 95% CI: 0.016-0.644). Moreover, time to relapse was significantly longer in patients who received postoperative immunosuppressive treatment compared to those who did not (p=0.013, log-rank test, Figure)

Conclusion: GIBS may presently acutely with perforation or severe bleeding requiring surgery, as the first manifestation. In this cohort 24% of GIBS patients required abdominal surgery and all except one were diagnosed with GIBS following the surgical procedure. Approximately 50% of the patients experienced a relapse, with most relapses occurring within 3 years. Among the patients who relapsed, 30% required reoperation. The use of immunosuppressive treatment after surgery showed a significant protective effect, reducing the risk of relapse by 90%.

Supporting image 1

Table. Demographic and characteristics of the patients

Supporting image 2

Figure. Relapse-free survival of patients who used postoperative immunosuppressive vs who did not


Disclosures: S. Esatoglu: None; S. Guner: None; S. Guler: None; G. Hatemi: None; N. Kepil: None; Y. Erzin: None; A. Celik: None; I. Hatemi: None.

To cite this abstract in AMA style:

Esatoglu S, Guner S, Guler S, Hatemi G, Kepil N, Erzin Y, Celik A, Hatemi I. Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/abdominal-surgical-interventions-among-patients-with-gastrointestinal-involvement-of-behcet-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abdominal-surgical-interventions-among-patients-with-gastrointestinal-involvement-of-behcet-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology